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Abstract
Background: Environmental impact assessments of pharmaceuticals typically consider only a part of the pharmaceutical
supply chain, e.g. tablet formulation. While the environmental impact can be expressed in environmental Human Health
burden due to resource use and emissions, the Human Health benefit of the pharmaceutical treatment of patients is
currently not simultaneously taken into account. The study aims include a cradle-to-grave assessment of all Human
Health impacts of the production, administration and disposal of two antipsychotics for the treatment of schizophrenia.
This is complemented with the environmental impact of health care providers such as hospitals. The aim is to holistically
quantify to what extent the environmental Human Health burden compares to the Human Health benefit associated
with the treatment.
Methods: We applied an overall framework which included Life Cycle Assessment to model the environmental Human
Health impacts of the pharmaceutical supply chain, administration and disposal of the drug and health care providers. To
model the patient benefit, this was complemented with a Markov model with a 1-year time horizon. Three patient
groups were modeled: medicine coverage of paliperidone palmitate for either one month (PP1M) or three months
(PP3M) at a time, and compared to Treatment Interruption (TI) as a control group. Outcomes were quantified using Years
of Life Lost (YLL), Years Lived with Disability (YLD) and Disability-Adjusted Life Years (DALY).
Results: The main environmental impacts were visits to the psychiatrist and psychiatric hospitals. The pharmaceutical
supply chain had a limited impact. For 1000 patients for 1 year, PP1M and PP3M respectively avoided 0.38 and 0.49
environmental DALYs compared to TI. PP1M and PP3M further avoided 45.60 and 57.87 YLL and 23.31 and 29.91 YLD
compared to TI. The main outcome was the sum of environmental DALYs, YLL and YLD, in which PP1M and PP3M
respectively avoided 69.29 and 88.26 DALYs. Alternative analysis of Quality-Adjusted Life Years confirmed the results.
Conclusions: The overall environmental burden was lower for PP1M and PP3M treatment than Treatment Interruption
because patients are kept more stable, which reduces the environmental burden due to hospitals. Moreover, the Human
Health burden was outweighed by the Human Health benefit.
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Background
The field of environmental impact assessment of
pharmaceutical products has evolved in recent years,
shifting its focus from the pharmaceutical supply chain
to a complete health care pathway. This has been made
explicit in guidance and policy documents by the
Sustainable Development Unit (SDU) of the English
National Health Service (NHS) [1].
The expansion of this scope should be reflected in the
inclusion of health care providers such as hospitals next
to the pharmaceutical supply chain, considering all
resource use and emissions of hazardous compounds
associated with care pathways [2–5]. In the field of Life
Cycle Assessment (LCA), these resources and emissions
can be linked to an environmental cause-effect chain,
which finally results in damage to three main Areas of
Protection (AoP): Natural Resources, Natural Environ-
ment and Human Health [6]. Traditionally LCA focuses
on the burden of the products and services it analyses,
with the benefit being defined as the products or
services themselves. However, health care pathways rep-
resent a clear Human Health benefit to patients, which
should be included in a holistic assessment and com-
pared to the environmental Area of Protection Human
Health burden. This is also recognized by the Swedish
national pharmaceutical strategy [7].
From the perspective of health care professionals, it is
now agreed that environmental criteria should be con-
sidered when making decisions on health care interven-
tions, as confirmed by health care decision makers from
key industrialized countries such as the US, Canada, UK
and Germany [8]. However, the methodology to simul-
taneously capture both the environmental impact and
the patient benefit of full health care pathways is cur-
rently missing.
We propose and evaluate a new approach and scope
that allows the holistic quantification of the full burden
and benefit of a health care pathway [9–11].
This demonstration study examines the treatment of
schizophrenia, which is a devastating, long-term illness
with a prevalence of around 0.7% worldwide [12]. The
occurrence of an acute psychotic episode or relapse se-
verely affects the quality of life and mortality of patients
[13, 14]. Treatment with antipsychotics is recommended
to manage psychotic symptoms and prevent relapse [15].
However, many patients show limited adherence and
multiple longer periods of interrupted treatment, which
are associated with worsening of symptoms and risk of
relapse [16–21]. This is a well-established challenge for
patients and families, which can be addressed by long-
acting antipsychotic injections, ensuring medical cover-
age for a number of weeks or months [22, 23]. This
study assesses the treatment effect of two long-acting
antipsychotic injections: paliperidone palmitate once-
monthly injection (PP1M) and paliperidone palmitate
three-monthly injection (PP3M). NanoCrystal® technol-
ogy is used to formulate the medicine suspension for
both PP1M and PP3M, but due to an increased particle
size PP3M has a longer sustained release of active ingre-
dient [24–28].
The performance of PP1M and PP3M is quantified with
a modified Cost-Effectiveness Analysis (CEA), as used by
the pharmaceutical industry and health care policy deci-
sion makers [29]. This approach covers how a patient
feels, functions and survives as a result of the pharmaceut-
ical treatment [30]. Two metrics that can be used to
express this effectiveness in patients’ quality and quantity
of life are the Quality-Adjusted Life Years (QALY) and
Disability-Adjusted Life Years (DALY) [31–35]. These
patient outcomes are then compared to the environmental
impact, which represents the ‘cost’ of the treatment.
This study aims to holistically quantify and compare
the global environmental Human Health burden due to
resource use and emissions and the patient Human
Health benefit from treatment, with the patient con-
sumption profile, calculated for each individual patient,
as a functional unit.
Methods
Overall framework
Figure 1 gives an indicative overview of the framework
applied in the study, with finer detail to follow. The
environmental Human Health burden is quantified by
accounting for all resource use and emissions from the
relevant actors and phases in both the pharmaceutical
supply chain and the health care providers. The Human
Health benefit is located at the center of the figure,
where the patient receives treatment.
The methodological framework is detailed in Fig. 2,
which shows the interaction between the Markov model
and the LCA. The Markov model determines the patient
health benefit and provides the patient consumption
profile. The Life Cycle Inventory (LCI) is then con-
structed followed by a Life Cycle Impact Assessment
(LCIA) to determine the Human Health burden. Both
the Human Health benefit and burden are then com-
pared and aggregated.
Part I: human health benefit
We define and compare three patient groups: treat-
ment with paliperidone palmitate once-monthly injec-
tion (PP1M), treatment with paliperidone palmitate
three-monthly injection (PP3M) and Treatment Inter-
ruption (TI).
Patients in Treatment Interruption are considered not
to request medical treatment on their own initiative.
However, once hospitalized for an unscheduled or un-
foreseen admission, these patients receive the same
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medical care as patients in the PP1M and PP3M treat-
ment groups.
Model structure and design
We developed a Markov model to simulate disease
outcomes of patients for PP1M and PP3M treatment, as
well as Treatment Interruption. The model was built in
Microsoft Excel. The population is a hypothetical Bel-
gian patient cohort eligible for the maintenance treat-
ment of schizophrenia [36–38]. In order to utilize
evidence from the Randomized Clinical Trials (RCT) of
paliperidone palmitate, we defined the age of the pa-
tients in the Markov model as 19–65 years, which
matches the age of the patients in the RCTs [39–41].
Before starting PP3M, patients first require an initiation
treatment on PP1M of four months. To align the model
with the structure of the RCT, we assumed that this
initiation was completed at the start of the model. The
patients in PP1M and TI have also completed initiation
on PP1M before the first model cycle.
The model envelops 5 health states. The ‘Stable:
Adherent’ state represents patients that are not in re-
lapse and are adherent to the medication. Patients in the
‘Stable: Non-adherent’ state are not in relapse but have
completely discontinued their medication. Patients in re-
lapse can be treated in a hospital or an ambulatory care
setting in respectively the ‘Relapse: Hospitalization’ and
‘Relapse: Ambulatory care’ states. The ‘Death’ state is the
absorbing state.
Figure 3 displays the model states. Moving from relapse
back to the stable states was found to be time-dependent.
Therefore we introduced tunnel states with different tran-
sition probabilities dependent on the time that patient
have stayed in the relapse state. A full description of the
tunnel states can be found in Additional file 1 , page 2–3.
PHARMACEUTICAL SUPPLY CHAIN
PATIENTS AND
HEALTH CARE PROVIDERS
Drug
administration
API synthesis
Drug
Production
Packaging Distribution &
Supply
End-of-Life
General
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General hospital
Psychiatric hospital
Ambulatory care
Psychiatrist
Fig. 1 Drug administration is where the patient and the pharmaceutical supply chain overlap
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Fig. 2 Interaction between Markov model and Life Cycle Assessment. Abbreviations: GP, general practitioner; PP1M, paliperidone palmitate once-
monthly injection; PP3M, paliperidone palmitate three-monthly injection; TI, treatment interruption
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All the patients are considered adherent in the first
cycle of the model. Patients in Treatment Interruption
do not request medical treatment on their own initiative.
Therefore, they are only adherent for the first model
cycle as a result of the remaining medicine coverage.
From the second cycle onwards patients can discontinue
treatment, experience a relapse, die or return to one of
the previous health states. Patients in the PP3M state
can only discontinue treatment every 3 months. We
defined relapse as an acute psychotic episode which can
be treated in either a hospital or an ambulatory care set-
ting. Many definitions of relapse of patients with schizo-
phrenia are mentioned in the literature including patient
functioning, events such as hospitalization and multiple
symptom rating scales. However, there is no golden
standard as yet [17, 42–44].
When patients recover from a relapse they return to
either the Adherent or Non-adherent state. When patients
return to the Stable: Adherent state they re-initiate PP1M
or PP3M medication through the recommended re-
initiation regimen.
We chose a time horizon of 1 year because of the pa-
tients’ tendency to switch to other treatments even
within a 1-year timeframe [45]. In this study we assume
that patients stay on or return to the same medication
throughout the year. We adopted a cycle length of 1
month to match the medical coverage of PP1M.
Transition probabilities
We used data from the clinical trials of paliperidone
palmitate and hospitals in Belgium. We carried out 9 lit-
erature reviews to further support the transition probabil-
ities. Real-world evidence was used when available and
secondary analysis was performed, for instance to isolate
the patient group diagnosed with schizophrenia. The
search strategies can be found in Additional file 1,
page 6–15. An overview of the transition probabilities can
be found in the Additional file 2: Tables A.5, A.6, A.7.
The monthly probability of relapse from the Stable:
Adherent state was obtained from Savitz et al. for PP1M
(0.0086) and for PP3M (0.0075) [41]. The monthly prob-
ability for relapse from the Stable: Non-adherent state
was obtained from the placebo arm in Hough et al. for
PP1M and TI (0.0639) and from the placebo arm in
Berwaerts et al. for PP3M (0.0282) [39, 40]. The placebo
arms in these studies were first stabilized on PP1M or
PP3M and then randomized to placebo. The fact that
patients on placebo are not fully discontinued is consid-
ered conservative, as fully discontinued patients would
be worse off due to less contact with health care profes-
sionals. Analysis of the literature agrees with the used
values, as detailed in Additional file 1, page 6–9.
According to a sub-set analysis of Lorant et al., 69% of
patients in relapse are hospitalized in Belgium [46].
Consequently, 31% are in ambulatory care.
The length of relapse was assumed equal for patients
who were hospitalized or in ambulatory care. For
hospitalization it was assumed that patients were first
brought to the general hospital following an acute re-
lapse episode. After two days the patients are transferred
to a psychiatric hospital for the remainder of the relapse
(Audenaert K., personal communication). This is the
case for general hospitals without a long-term psychi-
atric care unit. Two psychiatric hospitals provided recent
data on the average length of an admission. Data from
one hospital was sufficiently detailed for analysis. The
graph of hospital discharge over time was right skewed,
with outliers driving the mean to higher values. Most
patients were discharged before the mean duration, with
STABLE
Adherent
Non-adherent
RELAPSE
Hospitalization
(8 tunnel states)
Ambulatory care
(8 tunnel states)
Death
PP1M initiation
completed
Fig. 3 Markov model simulating the disease outcomes
Debaveye et al. BMC Health Services Research          (2019) 19:393 Page 4 of 16
some patients staying for longer periods. Given this
time-dependency of discharge, we introduced tunnel
states in the model. The same length of stay in a psychi-
atric hospital was assumed for PP1M or PP3M treat-
ment or Treatment Interruption.
After a relapse, patients have a 72% probability of
becoming Stable: Adherent and a 28% probability of
becoming Stable: Non-adherent [47].
We extracted the probability of treatment discontinu-
ation from [48], based on real-world evidence from filled
prescriptions at Belgian pharmacists. The monthly prob-
ability of discontinuation was 0.1200 for PP1M. Because
no evidence exists for PP3M, we extrapolated the differ-
ence in discontinuation between the biweekly injection
of Risperdal Consta and the monthly injection of PP1M.
This led to a three-monthly discontinuation probability
of 0.2816. The monthly probability of restarting the
initial drug after discontinuation was 0.1489.
The probability of death was calculated from the gen-
eral population mortality in Belgium [49]. We then
multiplied this with the Standardized Mortality Ratio
(SMR) for either stable schizophrenia or patients in re-
lapse. The former was obtained from Saha et al. as 2.58,
the latter from Hoang et al. as 6.2 [13, 50].
Disability sources and calculations
The disability of a disease can be weighted. A value of 0
represents no disability and 1 indicates full disability.
We adopted disability weights from the World Health
Organization (WHO) Global Burden of Disease (GBD)
2013 [51]. PP3M has a longer time between injections
and hence a reduced injection burden. However, we did
not assume a lower disability because of this. The dis-
ability weights did not include the occurrence of Ad-
verse Events (AE) such as Extra Pyramidal Symptoms
(EPS), weight gain or diabetes.
The disability weights can be found in Table 1. We
calculated the Years Lived with Disability (YLD) as
the disability weight of health state i (DW(i)) multi-
plied by the number of patients in health state i at
month t (p(i,t)) [33].
YLD i;tð Þ ¼ DW ið Þ  p i;tð Þ
Years of life lost (YLL)
When a patient dies in the model the Years of Life Lost
(YLL) are calculated as the number of deaths at age a
and month t (N(a,t)) multiplied by the Years of Life Lost
at age a (L(a)).
YLL a;tð Þ ¼ N a;tð Þ  L að Þ
The Years of Life Lost at death are 39.54, calculated
from people aged 19–65 (weighted mean age: 41.61) in
Belgium [49]. The fact that patients ‘age’ each month and
have a lower potential YLL as the model progresses was
taken into account. The YLL were not discounted [33].
The YLL are added to the YLD to calculate the
Disability-Adjusted Life Years (DALY):
DALY ¼ YLDþ YLL
We chose DALYs as the main outcome metric of this
study. Age-weighting or discounting of patient outcomes
was not considered as we followed the WHO guidelines
for the quantification of DALYs [33, 52]. We assessed
Quality-Adjusted Life Years (QALY) based on utility
values as a secondary outcome to validate the results.
Utility sources and calculations
Utility values represent the self-perceived wellbeing of a
person on a scale from 0 to 1 [34]. We obtained utility
values from Briggs et al. [53]. The study provides utility
values elicited from interviews with both patients and
laypersons. We chose to adopt the utility values from
the layperson group, which complies with the Belgian
guidelines and matches with the methodology of the
GBD disability values that are also weighted by the gen-
eral public [15, 52].
We complemented the utilities with the work of
Osborne et al., which studies the difference in utility based
on the time between injections in otherwise equal patients
[54]. The outcome suggests a significantly higher utility
Table 1 Disability weights and description of health states, available from Global Burden of Disease [51]
Health state Disability Health state description
Stable: Adherent 0.588 Schizophrenia: residual state
Hears and sees things that are not real and has trouble communicating.
The person can be forgetful, has difficulty with daily activities, and thinks
about hurting himself (or herself).
Stable: Non-adherent 0.588
Relapse: Hospitalization 0.778 Schizophrenia: acute state
Hears and sees things that are not real and is afraid, confused, and
sometimes violent. The person has great difficulty with communication
and daily activities, and sometimes wants to harm or kill himself (or herself).
Relapse: Ambulatory care 0.778
Death 1.000
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for patients that are adherent on PP3M. Both Briggs and
Osborne used the Time Trade-Off (TTO) method to elicit
utilities. We included utility decrements for the following
Adverse Events (AE): acute Extra Pyramidal Symptoms
(EPS), weight gain (> 7% increase) and diabetes. Medica-
tion use can trigger AE, therefore the decrements were in-
cluded in the Stable: Adherent state but also in the Stable:
Non-adherent state. The decrements were weighted de-
pending on the AE probability of occurrence in the Ran-
domized Clinical Trials (RCT) [39–41].
The utility values can be found in Table 2. We calcu-
lated QALYs by multiplying the utility value of health
state i with the time that population p spends in that
health state (t(i,p)) [29, 55].
QALY i;pð Þ ¼ Utility value ið Þ  t i;pð Þ
Part II: human health burden
Goal and scope
The goal is to quantify and compare the environmental
Human Health burden associated with PP1M or PP3M
treatment and Treatment Interruption. The functional
unit is the patient consumption profile, defined as the
use of health care pathway elements in Belgium for 1
year for 1000 patients. This includes the number of used
PP1M and PP3M syringes, visits to the GP and psych-
iatrist, ambulatory care visits and days spent in general
and psychiatric hospitals. The monthly use of health care
pathway elements per health state per patient is dis-
played in Table 3. Regardless of the frequency of anti-
psychotic injection, we consider three psychiatrist visits
per month for all stable patients, as psychiatrists also
provide general follow-up in addition to administering
medication (Audenaert K., personal communication).
We calculated the environmental impact of the health
care pathway elements with the Life Cycle Assessment
(LCA) methodology. This study focuses on the Human
Health burden associated with environmental impacts.
The health care pathway elements are reflected in the
scope of the LCA as previously shown in Fig 1. Both the
pharmaceutical supply chain and the health care pro-
viders are considered. The former envelops the Active
Pharmaceutical Ingredient (API) synthesis, drug produc-
tion, packaging, distribution & supply and End-of-Life
Table 2 Utility values of the health states [53, 54]
Health state Utility Source & calculation
PP1M
Stable: Adherent 0.865 Layperson sample
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
PP3M
Stable: Adherent 0.916 Layperson sample and added benefit for
time between injections
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
Treatment Interruption
Stable: Adherent 0.865 Layperson sample
Stable: Non-adherent 0.865 Assumed equal to Stable: Adherent
Relapse: Hospitalization 0.479 Layperson sample
Relapse: Ambulatory care 0.479 Layperson sample
Death 0.000 Assumed 0.000
Utility decrements for adverse events
Acute EPS 0.291 Layperson sample (0.865–0.574)
Weight gain 0.086 Layperson sample (0.865–0.779)
Diabetes 0.153 Layperson sample (0.865–0.712)
Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; EPS, Extrapyramidal Symptoms
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phases. The latter contains General Practitioner (GP)
and psychiatrist, ambulatory care, psychiatric hospitals
and general hospitals. The two fields overlap at the drug
administration.
The LCA includes the use of chemicals, energy
sources, transport, water, industrial waste treatment,
packaging materials and End-of-Life disposal and fate of
the drug. The cost of infrastructure does not allow clear
allocation to the product, due to the uncertain lifetime
of fixed equipment and buildings and is therefore not
taken into account.
Methodology
The data and results in this study were obtained, proc-
essed and are presented according to the ISO 14040 and
ISO 14044 series [56, 57] and International Reference
Life Cycle Data System (ILCD) guidelines [58–60]. One
exception is made for the Human Health endpoint indi-
cator, as ISO 14044 does not support the grouping of
midpoint impact categories into endpoints. The ILCD
does support the use of endpoint indicators, although
some of the midpoint indicators used to calculate this
endpoint receive an interim recommendation [59]. The
main part of the Human Health burden is attributable to
Climate Change and Particulate Matter Formation which
both receive the highest classification (classification I:
recommended and satisfactory) on the midpoint level.
On the endpoint level, Climate Change is proposed as
the best among the analyzed methods while Particulate
Matter Formation receives classification I/II (recom-
mended and satisfactory/recommended but in need of
some improvements). The Life Cycle Impact Assessment
(LCIA) clearly details which characterization factors
were used.
Life cycle inventory
The inventory for the pharmaceutical supply chain was
gathered on-site at the Janssen Pharmaceutica sites in
Cork (Ireland), Geel and Beerse (Belgium). The system
boundaries of the foreground processes (the processes
that were analyzed in detail) were the limits of the pro-
duction plants. In addition, we also included the off-site
industrial waste treatment operations such as distillation
or incineration that were outsourced to third parties.
Transport of the intermediate products between the
Cork, Geel and Beerse sites was also taken into account.
We included the basic unit operations as well as the
main plant supporting processes. Primary data was used,
all life cycle stages were included and the electricity mix
was adapted depending on the origin of the electricity
per production site.
Data for the API chemical synthesis of the active in-
gredient paliperidone palmitate and Drug Production of
the PP1M and PP3M syringes was retrieved from Batch
Production Reports, Cleaning Procedures, Equipment
Manuals, yearly planning and partly through a shortcut
LCA tool developed by Van der Vorst et al. specifically
for the production plant in Geel [61]. The differences in
NanoCrystal® formulation between PP1M and PP3M
were included. The resource use of supporting processes
such as heating, cooling and generation of purified water
and steam was included. The (air) Heating, Ventilation
and Air Conditioning (HVAC) system was included for
the production in Cork and Beerse but not for Geel.
This is a limitation as the LCA tool by Van der Vorst
et al. does not include the HVAC system [61]. The in-
dustrial waste treatment of water-based and organic
waste was taken into account.
As the PP1M and PP3M medicines come in different
dosages, it was chosen to analyze the environmental bur-
den of the dosage with the highest market share, which
is 100 mg-eq. for PP1M and 350mg-eq. for PP3M (Jans-
sen Pharmaceutica, personal communication). The dos-
age in mg equivalents reflects the mass of the
pharmacologically active compound paliperidone, where
e.g. 100 and 350 mg-eq. relate to 156 mg and 546 mg
paliperidone palmitate respectively.
The Packaging included the electricity use and HVAC
of the packaging line and the primary, secondary and
tertiary packaging materials. Packaging materials specific
Table 3 The monthly use of health care pathway elements per health state per patient
Health state Syringes GP visits Psychiatrist visits Ambulatory care visits General hospital
bed days
Psychiatric hospital
bed days
Stable: Adherent PP1M 1 PP1M syringe 0.3 3 0 0 0
Stable: Adherent PP3M 0.33 PP3M syringe 0.3 3 0 0 0
Stable: Non-adherent 0 0.3 3 0 0 0
Relapse: Ambulatory care 0 0 6.2 2.17 0 0
Relapse: Hospitalization month 1 0 0 0 0 2 28
Relapse: Hospitalization month 2-8a 0 0 0 0 0 30
Death 0 0 0 0 0 0
Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; GP, General Practitioner
aPatients can stay in the 8th hospitalization state for multiple cycles, see Additional file 1, page 2–3
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for the Belgian market were analyzed. Rejections by
visual inspection of the syringe before packaging were
included.
The Distribution & Supply included the transport
from the production site in Beerse (Belgium) to the
European distribution center in La Louvière (Belgium).
This was added to the average distance from the
distribution center to a Belgian psychiatrist (69.225 km),
who administers the medicine in this model. The latter
was calculated by the Geography department at Ghent
University (Fransen K., personal communication). The
yearly returns and destructions were included.
The End-of-Life phase considers paliperidone, the
active metabolite of paliperidone palmitate. The total
mass of paliperidone administered to the patient is
subtracted by the percentage of API metabolized in the
patient (41%) and removed in the WWTP (64%)
(Janssen Pharmaceutica, personal communication). For
the latter an approximation was used from Vergeynst
et al. based on risperidone, which is identical to paliperi-
done except for one hydroxyl group [62].
The End-of-Life is based on Environmental Risk As-
sessment (ERA). When multiple measurements were
available, e.g. for KOC (the adsorption coefficient), the
worst-case value was adopted. The End-of-Life assess-
ment also included the waste disposal of the pack-
aging materials and the hazardous waste disposal of
the syringe.
Secondary data for the background processes (the pro-
cesses that support the foreground) such as energy and
chemicals were extracted from the ecoinvent v3.1 data-
base using SimaPro v8 software [63].
The LCI of the health care providers consists of the
average transport distance and the on-site energy and
water use.
The average transport distance from a Belgian house-
hold to the closest three GP’s (1.091 km) or psychiatrists
(7.055 km) and the closest hospital (10.933 km) was calcu-
lated by the Geography department at Ghent University
(Fransen K., personal communication). The transport was
assumed by car, as a modal split for health care-related
transport was not readily available. The number of visits
to the GP and psychiatrist was based on results from an
expert panel of Belgian psychiatrists [64].
For the general and psychiatric hospitals we included
the directly measured energy and water use based on
yearly reporting figures, recalculated per bed day. The
energy included electricity, natural gas and fuel. Any off-
site generation of e.g. heat was not included. Data was
obtained from 3 general hospitals and 5 psychiatric hos-
pitals in the Flanders region. The general hospitals were
the UZ Ghent hospital (Ghent), part of the UZ Leuven
hospital (Leuven) and the AZ St. Lucas hospital (Ghent).
The psychiatric hospitals were St. Camillus (Sint-Denijs-
Westrem), PC Caritas (Melle), Dr. Guislain (Ghent), St.
Jan (Eeklo) and Zoete Nood Gods (Lede). The amount
of beds represented was 1981 for the general hospitals
and 1071 for the psychiatric hospitals. A possible reduc-
tion in resource use at the home of the patient was not
taken into account.
Patients in the Relapse: Ambulatory care state receive
house visits from a nurse. In this case the nurses visit
several patients in a row. Data from the mobile team at
the Psychiatric Centre Gent-Sleidinge was used to calcu-
late the average number of visits per month (2.17) and
transport distance by car per patient (5.17 km). This is
based on a total of 3018 house visits.
Life cycle impact assessment
The Impact Assessment focused on the impact categories
with an effect on Human Health: Climate Change, Human
Toxicity, Ionizing Radiation, Ozone Depletion, Particulate
Matter Formation and Photochemical Oxidant Formation
[65–69]. These were used to calculate the EndPoint
Human Health burden through the ReCiPe v1.11 impact
assessment method, which is identified as the best practice
model for Human Health burden [6, 60, 70, 71].
The End-of-Life impact assessment of the molecule
considered emissions to continental freshwater using the
USEtox methodology [60, 72].
The results of the impact assessment were subdivided
according to the type of resource or service: water, nitro-
gen, chemicals (reagents and solvents), energy (natural
gas, electricity, fuel), packaging materials, industrial
waste treatment, transport and End-of-Life.
Value choices
The Human Health damage can be calculated using dif-
ferent sets of Value Choices, each representing specific
requirements for the discounting and considered time
horizon of environmental effects. The Value choices also
include the age-weighting of populations on which the
environmental effects manifest [73, 74]. The consensus-
driven Hierarchical perspective was chosen. This per-
spective considers a long time horizon for environmental
effects to manifest and bases itself on scientific consen-
sus, as opposed to the Individualist (optimistic) and
Egalitarian (pessimistic) perspectives [59]. The use of a
0% discount factor and the avoidance of age-weighting is
consistent with the assessment of disease outcomes
resulting from treatment used in the Markov model.
The applied time horizon for the Human Health damage
is 100 years, which does not correspond to the 1-year
time horizon used in the Markov model. However,
matching time horizons in this case would not benefit
the research. On the contrary, given that effects of com-
pounds take years, if not decades to manifest in the
environment it is opportune to choose two different
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time horizons: a short and manageable time horizon for
the patient outcomes and longer time horizon to capture
the environmental effects [6].
Towards a net health effect
Both the patient health benefit and the environmental
Human Health burden of a pharmaceutical treatment
can be expressed in DALYs. Therefore we propose to
merge these two outcomes into a single score. We calcu-
late the ‘net health effect’ (DALYnet) as:
DALYpatient ¼ YLDpatient þ YLLpatient
DALYnet ¼ DALYpatient þ DALY env
With YLDpatient the disability of the 1000 patients,
YLLpatient the loss of life years of the patients, DALYpati-
ent the sum of the previous and DALYenv the environ-
mental DALYs. The DALYnet is then calculated and
compared across treatment with PP1M or PP3M and
Treatment Interruption.
Sensitivity analysis
A sensitivity analysis was performed as defined in Add-
itional file 1, page 18–20. The sensitivity of the Markov
model inputs with respect to the Human Health benefit
was assessed. As the patient consumption profile is based
on the same inputs, a range of environmental Human
Health burden results was obtained at the same time.
Results
The disease outcomes of the Markov model for 1000 pa-
tients during 1 year, as well as the environmental burden
are listed in Table 4. TI, PP1M and PP3M scenarios
yielded 626.80, 603.49 and 596.90 YLDs respectively,
resulting in an YLD reduction of 23.31 (− 3.72%) and
Table 4 Patient consumption profile and Human Health benefit and burden results
1. Patient consumption profile TI PP1M PP3M
Syringes (1 M) – 8055 94
Syringes (3 M) – – 2564
GP visits 2883 3322 3447
Psychiatrist visits 34,109 35,224 35,528
Ambulatory care visits 1849 701 371
General hospital bed days 791 335 178
Psychiatric hospital bed days 43,864 16,406 8699
2. Human Health benefit
Years Lived with Disability (YLD)
Total patient YLDs 626.80 603.49 596.90
ΔYLDs of treatment vs. TI (%) – −23.31 (−3.72%) −29.91 (−4.77%)
Years of Life Lost (YLL)
Total patient YLLs 346.23 300.63 288.36
ΔYLL of treatment vs. TI (%) – −45.60 (−13.17%) −57.87 (−16.71%)
Disability-Adjusted Life Years (DALY) = YLD + YLL
Total patient DALYs 973.03 904.12 885.26
ΔDALY of treatment vs. TI (%) – −68.91 (−7.08%) −87.77 (−9.02%)
Quality-Adjusted Life Years (QALY)
Total patient QALYs 785.22 830.54 881.35
ΔQALY of treatment vs. TI (%) – + 45.32 (+ 5.77%) + 96.13 (+ 12.24%)
3. Human Health burden
Environmental DALYs
Total environmental DALYs 0.954 0.579 0.468
ΔDALYs of treatment vs. TI (%) – −0.375 (−39.32%) −0.487 (−51.00%)
4. Net Human Health effects (net DALYs = YLD + YLL + environmental DALYs)
Total net DALYs 973.98 904.70 885.73
ΔDALY of treatments vs. TI – −69.29 (−7.11%) −88.26 (−9.06%)
Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; TI, Treatment Interruption
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29.91 (− 4.77%) for PP1M and PP3M respectively com-
pared to TI.
The Years of Life Lost (YLL) were 346.23, 300.63
and 288.36 YLL for TI, PP1M and PP3M respectively,
resulting in an YLL reduction of 45.60 (− 13.17%) and
57.87 (− 16.71%) for PP1M and PP3M respectively
compared to TI.
Hence, TI, PP1M and PP3M resulted in 973.03, 904.12
and 885.26 DALYs respectively. Compared to TI, PP1M
and PP3M avoided 68.91 (− 7.08%) and 87.77 (− 9.02%)
DALYs respectively.
The alternative analysis yielded 785.22, 830.54 and
881.35 QALYs for TI, PP1M and PP3M, which resulted in
a QALY gain of 45.32 (+ 5.77%) and 96.13 (+ 12.24%)
QALYs for PP1M and PP3M respectively compared to TI.
Analysis of environmental Human Health burden re-
sulted in 0.954, 0.579 and 0.468 environmental DALYs
for TI, PP1M and PP3M respectively. Compared to TI,
PP1M and PP3M avoided 0.375 (− 39.32%) and 0.487
(− 51.00%) environmental DALYs respectively.
The net DALY burden including both patient and en-
vironmental outcomes amounted to 973.98, 904.70 and
885.73 DALYs for Treatment Interruption or treatment
with PP1M or PP3M respectively, which resulted in a
DALY reduction of 69.29 (− 7.11%) and 88.26 (− 9.06%)
for PP1M and PP3M respectively compared to TI.
The environmental Human Health burden was di-
vided in three main parts shown in Fig. 4: the pharma-
ceutical supply chain, visits to the GP or psychiatrist
as well as ambulatory care visits and general and psy-
chiatric hospitals. Table 5 provides more detailed re-
sults with a subdivision concerning the resource type.
The difference between industrial waste treatment and
End-of-Life is that the former concerns treatment of
waste from pharmaceutical production sites, whereas
the latter envelops post-consumer waste. The negative
values in the table were caused by waste incineration
processes with energy recovery. This avoided the use
of virgin resources and was accounted as an environ-
mental gain. A table with a subdivision on midpoint
categories can be found in Additional file 1, page
16–17.
For PP1M 54.48% of the environmental DALYs origi-
nated from psychiatrist visits, 36.59% from psychiatric
hospital stays, 5.28% from general hospital stays and
2.46% from the pharmaceutical supply chain. For PP3M
68.04% resulted from psychiatrist visits, 24.03% from
psychiatric hospital stays, 3.18% from the pharmaceutical
supply chain and 3.47% from general hospital stays. For
TI 59.36% was caused by psychiatric hospital stays,
32.01% from psychiatrist visits and 7.57% by general
hospitals stays.
Visits to the psychiatrist and hospitalization in psychi-
atric hospitals caused the bulk of the Human Health
burden. When looking at the underlying resource use
for psychiatric hospitals, 78.27% of the total Human
Health burden was due to electricity use, 11.19% due to
fuel consumption and 8.87% due to natural gas use.
Hospitalization in general hospitals represented only 2
days per full hospitalization, and was therefore respon-
sible for a large DALY/day contribution. For the general
hospitals 57.66% of the total burden was due to electri-
city use and 40.93% due to fuel consumption. Conse-
quently, car transport and electricity use in hospitals
were the main cause of Human Health burden.
Ambulatory care performed significantly better than
hospitalization, contributing 0.40, 0.26 and 0.64% of the
total environmental DALYs for PP1M, PP3M and TI
respectively. The End-of-Life phase, a part of the supply
chain with traditionally a high focus on environmental
concerns had a negligible contribution to the total
Human Health burden.
The results of the one-way and probabilistic sensitivity
analysis can be found in Additional file 1, page 18–20.
Overall, the model was robust in the sense that the con-
clusion did not change in any of the analysis.
0.00E+00 2.00E-01 4.00E-01 6.00E-01 8.00E-01 1.00E+00
PP3M
PP1M
TI
Disability-Adjusted Life Years (DALY) for 1000 patients for 1 year
Pharmaceutical supply chain
Visits to GP or psychiatrist,
ambulatory care visits
General and psychiatric hospitals
Fig. 4 Environmental Human Health burden in Disability-Adjusted Life Years (DALYs): Abbreviations: GP, General Practitioner; PP1M, paliperidone
palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; TI, Treatment Interruption
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Table 5 Environmental Human Health burden in Disability-Adjusted Life Years (DALYs)
TI API Drug
Production
Packaging Distribution
& Supply
End-of-Life
disposal
& drug fate
GP
visits
Psychiatrist
visits
Ambulatory
care visits
General
hospital days
Psychiatric
hospital days
Water N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 2.20E-04 3.99E-03
Nitrogen N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Reagents N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Solvents N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Energy - Natural Gas N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 7.20E-04 4.29E-02
Energy - Electricity N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 3.85E-02 3.79E-01
Energy - Fuel N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 2.73E-02 5.41E-02
Packaging materials N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Industrial waste
treatment
N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Transport N/A N/A N/A N/A N/A 3.99E-03 3.06E-01 6.08E-03 5.49E-03 8.70E-02
End-of-Life N/A N/A N/A N/A N/A 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
PP1M
Water 1.72E-06 4.38E-07 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 9.32E-05 1.49E-03
Nitrogen 6.25E-05 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Reagents 1.41E-03 1.89E-05 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Solvents 5.94E-04 6.76E-08 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Energy - Natural Gas 2.43E-03 2.06E-03 8.96E-04 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 3.05E-04 1.60E-02
Energy - Electricity 2.74E-03 1.48E-04 7.95E-05 −7.29E-06 −4.02E-04 0.00E+
00
0.00E+ 00 0.00E+ 00 1.63E-02 1.42E-01
Energy - Fuel 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 1.16E-02 2.02E-02
Packaging materials ND 4.36E-08 2.65E-03 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Industrial waste
treatment
9.95E-04 5.12E-07 0.00E+ 00 6.01E-06 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Transport 1.61E-05 0.00E+ 00 1.16E-04 5.13E-05 0.00E+ 00 4.60E-03 3.16E-01 2.30E-03 2.33E-03 3.25E-02
End-of-Life ND ND 0.00E+ 00 0.00E+ 00 3.75E-04 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
PP3M
Water 2.19E-06 5.67E-07 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 4.95E-05 7.92E-04
Nitrogen 7.94E-05 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Reagents 1.79E-03 2.28E-05 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Chemicals - Solvents 7.55E-04 8.59E-08 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
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Discussion
The environmental Human Health burden is reduced
for PP1M and PP3M compared to TI because of a
decrease in hospitalization. Within the pharmaceutical
supply chain the largest environmental impact is associ-
ated with the API synthesis. However, the health care
providers together represent an impact 40 and 30 times
larger than the pharmaceutical supply chain of PP1M
and PP3M, respectively. Visits to the psychiatrist and
psychiatric hospitals were the main hotspots. This rein-
forces the need for holistic assessments when analyzing
the environmental performance of health care pathways.
Maintenance treatment of schizophrenia with PP1M
and PP3M also leads to less patient DALYs than TI
because the treatments prevent relapse. There is a strik-
ing difference in order of magnitude between the
avoided patient DALYs and environmental DALYs: re-
spectively 184 and 180 times more patient DALYs than
environmental DALYs were avoided for PP1M and
PP3M versus TI.
This is one of the first attempts to holistically quantify
the Human Health benefit and burden of a full health
care pathway. We expanded the environmental impact
assessment of a health care pathway to include both the
pharmaceutical supply chain and health care providers,
for which multiple primary data sources were used.
Methodologies from different fields of research were
combined in a new quantitative approach, using a com-
mon metric for the Human Health performance of
health care pathways.
The limitations of the study that should be noted are
the following. Even though real-world evidence was used
when available, the results of the Markov model are in-
fluenced by the Randomized Clinical Trials (RCT) that
provided input data. Hence, the results of the Markov
model should not be considered as real-world patient
benefits or burdens. The one-way sensitivity analysis in
Additional file 1, page 18–19 shows that the duration of
relapse is the most sensitive parameter. Data availability is
a limitation here, as this calculation is based on data from
one hospital. The model was robust and not particularly
sensitive to other parameters. The conclusion did not
change in any of the sensitivity analysis. It should however
be noted that the sensitivity analysis was based on point
estimates, which were varied by the standard deviation,
or ± 20% if the former was not available.
The results for both patient YLDs and QALYs are
high. This may seem contradictory, as a high number of
YLDs should be associated with a low number of
QALYs. This can be partly explained by the origin of the
disability weights and utility values. The Global Burden
of Disease (GBD) includes self-harm as part of the
disability description of both stable schizophrenia and
relapse, which may partly explain the high disability rat-
ing [51]. Furthermore, the health state description of the
GBD details severe symptoms, even for the residual or
stable state. We consider this to be a conservative
approach. The descriptions in Briggs et al. are less severe
and do not include self-harm [53].
Both YLDs and QALYs could have been used as the
main reporting metric on treatment impact on Human
Health. In this case, we preferred YLDs for two reasons.
First, the delta disability between stable schizophrenia
and relapse is smaller, resulting in a more conservative
benefit of avoided YLDs for treatment with PP1M or
PP3M compared to TI. There is also no additional bene-
fit for PP3M in the Stable: Adherent state. This can be
considered a conservative approach. Second, the use of
DALYs as a patient outcome matches the use of DALYs
as an environmental Human Health burden metric in
Table 5 Environmental Human Health burden in Disability-Adjusted Life Years (DALYs) (Continued)
TI API Drug
Production
Packaging Distribution
& Supply
End-of-Life
disposal
& drug fate
GP
visits
Psychiatrist
visits
Ambulatory
care visits
General
hospital days
Psychiatric
hospital days
Energy - Natural Gas 3.09E-03 2.62E-03 3.33E-04 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 1.62E-04 8.51E-03
Energy - Electricity 3.48E-03 1.88E-04 2.98E-05 −3.18E-06 −1.45E-04 0.00E+
00
0.00E+ 00 0.00E+ 00 8.66E-03 7.51E-02
Energy - Fuel 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 6.14E-03 1.07E-02
Packaging materials ND 7.57E-08 1.10E-03 0.00E+ 00 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Industrial waste
treatment
1.26E-03 6.51E-07 0.00E+ 00 2.62E-06 0.00E+ 00 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Transport 2.04E-05 0.00E+ 00 4.65E-05 2.24E-05 0.00E+ 00 4.77E-03 3.18E-01 1.22E-03 1.24E-03 1.73E-02
End-of-Life ND ND 0.00E+ 00 0.00E+ 00 1.48E-04 0.00E+
00
0.00E+ 00 0.00E+ 00 0.00E+ 00 0.00E+ 00
Abbreviations: PP1M, paliperidone palmitate once-monthly injection; PP3M, paliperidone palmitate three-monthly injection; TI, Treatment
Interruption; API, Active Pharmaceutical Ingredient; GP, General Practitioner; ND, Non-Determined; N/A, Not Applicable
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Life Cycle Assessment (LCA). This enables a direct com-
parison between both fields of research.
The LCA also has limitations. We only considered car
transport for visits to the GP or psychiatrist. For the
general and psychiatric hospitals we included energy
sources and water but not the food, cleaning or other
procurement. When patients relapse, health care pro-
viders administer emergency medication to suppress the
symptoms. This medication was not included in the as-
sessment, which is considered a conservative approach.
The negligible environmental impact of the End-of-Life
phase could be questioned. We chose a consensus model
out of the multiple toxicity models that are available
[72]. There is also a large spread in Absorption, Distribu-
tion, Metabolism, Excretion (ADME) and toxicity proper-
ties of drug substances [3, 75]. The small environmental
impact could also be explained by the low dose regimen
of the medicine. Therefore, the contribution of End-of-
Life to the total impact in this case is not representative
for all pharmaceuticals, although it does indicate that a
broader focus may be warranted when considering the
impact of pharmaceuticals in the environment.
There is an ongoing discussion on the grouping of mid-
point categories to calculate endpoints in Life Cycle As-
sessment. We argue that it is justified in this case because
of the opportunity to make a direct comparison between
the Human Health benefit and burden [76]. Midpoint
indicators are not suited to reflect this burden and only
consider effects. However, we acknowledge the criticism
of endpoint modeling for its high uncertainty [77].
We identified one prior study reporting patient and en-
vironmental outcomes of a pharmaceutical treatment [78].
For the treatment of type 2 diabetes, patient outcomes are
reported in QALYs and the environmental assessment is
in kg CO2 emissions. The carbon intensity of the treat-
ment is obtained through a cost-based top-down approach
of the average carbon footprint of pharmaceutical prod-
ucts procured by the NHS. While offering a transparent
and simple method to include environmental impacts in
health economic analysis, the results are not directly com-
parable to the outcomes in this study.
The English National Health Service (NHS) Sustainable
Development Unit (SDU) reports that in 2015 pharma-
ceuticals were responsible for 11% of the total Carbon
Footprint of the NHS [79]. The energy use of buildings is
associated with 18% of the Carbon Footprint and trans-
port causes 13% of the impact. The SDU uses a different
environmental impact method: the Carbon Footprint.
However, it is closely linked to Human Health damage, for
which Climate Change is typically the main driver.
The results of the SDU suggest a higher contribution of
pharmaceuticals and a lower contribution of buildings and
transport than reported in this study. This could be attrib-
uted to the difference in scope. The SDU considers the full
health care system while this study focuses on one disease
area. The analysis was also performed in a different coun-
try. Transport and the degree and type of hospitalization
are specific for each disease area and country. Further-
more, the drug dose per day in this study is low.
There is also a difference in approach. The care pathway
modules defined by the SDU are similar to the health care
pathway elements used in this study [1]. However, the
SDU uses a top-down approach which enables a fast as-
sessment of a full health care system. The current study
uses a data intensive, but more detailed bottom-up ap-
proach that also includes the benefits at the service level.
The results of this study are specific for the treatment
of patients with schizophrenia with long-acting anti-
psychotic injections in the Flanders region of Belgium.
The findings suggest that treatment with PP1M and
PP3M avoids Human Health burden for both patients
and the environment. Three suggestions are proposed to
enlarge this benefit even more.
First, ambulatory care could be promoted over
hospitalization. If this is feasible from a treatment per-
spective, it would reduce the environmental Human
Health burden considerably. Second, hospitals could
reduce the impact of their electricity consumption by
opting for a cleaner and more renewable energy mix.
Third, environmentally sustainable transport in health
care could be promoted. This is probably already the
case, as we assumed that all transport is by car, where in
reality patients might use public transport.
Our data suggest that academics and policymakers
evaluating a pharmaceutical treatment should consider
the full health care pathway including all environmental
and patient Human Health impacts.
The outcomes of this study should be further tested
and validated with research on other disease areas,
countries, health care settings and standards. It is un-
likely that the pharmaceutical treatment of patients will
avoid environmental Human Health burden in all dis-
ease areas. For instance, the results of this study could
be compared to a health care pathway with less intensive
contact with health care providers and a higher daily
dose of medication. This could provide further insights
in the relationship between the health care providers
and the pharmaceutical supply chain with respect to the
ranges of Human Health burden.
The environmental part of this study only considers im-
pacts on Human Health. Other Areas of Protection (AoP),
such as depletion of natural resources and damage to the
natural environment may be considered for inclusion in
future studies to capture all environmental aspects.
Conclusions
We consider the treatment of patients with schizophrenia
in Belgium with paliperidone palmitate once-monthly or
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paliperidone palmitate three-monthly long-acting injec-
tions. The treatments are compared with Treatment Inter-
ruption and reduce the cradle-to-grave environmental
Human Health burden, quantified as Disability-Adjusted
Life Years (DALYs), because of a lower risk of relapse,
leading to a reduction of hospitalization. Apart from
hospitalization, car transport of patients represents the
largest environmental Human Health burden. The treat-
ments represent a clear Human Health benefit for the
patients quantified as avoided DALYs, which is compared
to the avoided burden using a common metric. The re-
sults of this demonstration study can help policymakers to
identify and address the environmental Human Health
hot spots of the treatment of schizophrenia in Belgium.
The patient health benefit in avoided DALYs is several
orders of magnitude larger than the global environmen-
tal DALYs. Additionally, the environmental Human
Health burden is reduced by treatment because of a
lower risk of relapse, which reduces hospitalizations.
This benefit versus benefit conclusion is opposed to the
benefit versus burden result that one would expect [9].
While this study provides a first insight in the holistic
quantification of the Human Health benefit and burden of
a full health care pathway, these findings should be vali-
dated and contrasted with research based on real-world
data in different disease areas and in multiple countries.
Additional files
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assumptions and limitations, literature reviews, Life Cycle Assessment
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Additional file 2: Transition probability matrices for the Markov model.
(XLSX 14 kb)
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